课题基金 / 基金详情

Mechanisms of Neurodegeneration in Lewy Body Disorders

Mechanisms of Neurodegeneration in Lewy Body Disorders
路易体疾病的神经变性机制
批准号:
9362192
负责人:
Vivek Unni
金额:
$38.5万
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-07-01 至 2022-03-31

项目摘要

项目成果

Vivek Unni的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY One major obstacle to halting neurodegeneration in synucleinopathies like Parkinson's Disease (PD) and Dementia with Lewy Bodies (DLB) is a lack of understanding of why vulnerable cell populations die. Although aggregated alpha-synuclein Lewy pathology occurs within specific neurons, and their dysfunction or degeneration leads to symptoms in these diseases, how Lewy pathology itself plays a role is unclear. Recent work by the Unni lab has discovered a previously unrecognized function for the protein alpha-synuclein in repairing nuclear DNA double-strand breaks (DSB), by using newly developed in vivo multiphoton imaging techniques to study alpha-synuclein aggregation in mice. These approaches have now been extended (for the first time) to study DNA repair in living mouse brain. The unexpected function for alpha-synuclein immediately suggests an exciting new hypothesis for the role of aggregated alpha-synuclein Lewy inclusions in neurodegeneration. This central hypothesis is that in disease, alpha-synuclein protein is sequestered in cytoplasmic Lewy bodies, decreasing its nuclear DSB repair function and leading to cell death of Lewy body- containing neurons. Furthermore, it is proposed that the source of fibrillar α-synuclein that initially seeds Lewy body formation comes from dysregulated DSB repair. The preliminary data suggest this complex interrelationship, with alpha-synuclein aggregation causing dysregulated DSB repair and vice versa. Although completely novel, this link between alpha-synuclein and DSB repair could explain previously poorly understood associations between human and mouse mutations in the DSB repair protein Ataxia-Telangiectasia Mutated and alpha-synuclein aggregation, and between specific synuclein family members and cancer (e.g. alpha- synuclein & melanoma, gamma-synuclein & breast cancer). This proposal will use a combination of advanced imaging approaches in purified, reconstituted in vitro systems, in mouse brain in vivo, and in mouse & human (PD, DLB) fixed tissue to test how alpha-synuclein mediates DSB repair (Aim 1), how loss of nuclear α- synuclein function after cytoplasmic Lewy inclusion formation dysregulates DSB repair and contributes to neuronal cell death (Aim 2), and how dysregulated DSB repair can lead to Lewy inclusion formation (Aim 3). Overall, this project is innovative because it uses powerful, new in vivo experimental approaches to test a fundamentally new hypothesis for how alpha-synuclein aggregation into Lewy pathology is related to neurodegeneration. This contribution will be significant because it will provide a completely new set of targets for treating these debilitating neurodegenerative disorders that focuses on the DSB repair pathway, and because understanding alpha-synuclein-mediated DSB repair in detail will increase our basic science knowledge of this important biological process.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Mechanisms of spreading proteinopathy in Lewy Body Dementia
Mechanisms of Neurodegeneration in Lewy Body Disorders
Mechanisms of Neurodegeneration in Lewy Body Disorders
Mechanisms of neuronal cell death in synucleinopathies
国内基金
海外基金
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
  • 批准号:
    LBY21H010001
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2020
  • 负责人:
    郑绪阳
  • 依托单位:
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
  • 批准号:
    81703335
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    20.0万元
  • 批准年份:
    2017
  • 负责人:
    卫高菲
  • 依托单位:
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
  • 批准号:
    81670594
  • 项目类别:
    面上项目
  • 资助金额:
    58.0万元
  • 批准年份:
    2016
  • 负责人:
    陈昊
  • 依托单位:
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
  • 批准号:
    81470791
  • 项目类别:
    面上项目
  • 资助金额:
    73.0万元
  • 批准年份:
    2014
  • 负责人:
    董家鸿
  • 依托单位: